Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment

D. James Haddon, Hannah E. Wand, Justin A. Jarrell, Robert F. Spiera, Paul J. Utz, Jessica K. Gordon and Lorinda S. Chung

J Rheumatol 2017;44;631-638
http://www.jrheum.org/content/44/5/631

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment

D. James Haddon, Hannah E. Wand, Justin A. Jarrell, Robert F. Spiera, Paul J. Utz, Jessica K. Gordon, and Lorinda S. Chung

**ABSTRACT.** **Objective.** Imatinib has been investigated for the treatment of systemic sclerosis (SSc) because of its ability to inhibit the platelet-derived growth factor receptor and transforming growth factor-β signaling pathways, which have been implicated in SSc pathogenesis. In a 12-month open-label clinical trial assessing the safety and efficacy of imatinib in the treatment of diffuse cutaneous SSc (dcSSc), significant improvements in skin thickening were observed. Here, we report our analysis of sera collected during the clinical trial.

**Methods.** We measured the levels of 46 cytokines, chemokines, and growth factors in the sera of individuals with dcSSc using Luminex and ELISA. Autoantigen microarrays were used to measure immunoglobulin G reactivity to 28 autoantigens. Elastic net regularization was used to identify a signature that was predictive of clinical improvement (reduction in the modified Rodnan skin score ≥ 5) during treatment with imatinib. The signature was also tested using sera from a clinical trial of nilotinib, a tyrosine kinase inhibitor that is structurally related to imatinib, in dcSSc.

**Results.** The elastic net algorithm identified a signature, based on levels of CD40 ligand, chemokine (C-X-C motif) ligand 4 (CXCL4), and anti-PM/Scl-100, that was significantly higher in individuals who experienced clinical improvement than in those who did not (p = 0.0011). The signature was validated using samples from a clinical trial of nilotinib.

**Conclusion.** Identification of patients with SSc with the greatest probability of benefit from treatment with imatinib has the potential to guide individualized treatment. Validation of the signature will require testing in randomized, placebo-controlled studies. Clinicaltrials.gov NCT00555581 and NCT01166139.

(First Release March 15 2017; J Rheumatol 2017;44:631–8; doi:10.3899/jrheum.160833)
Systemic sclerosis (SSc) is a chronic disease characterized by fibrosis and vascular dysfunction affecting the skin and internal organs. Individuals with diffuse cutaneous SSc (dcSSc) experience substantial morbidity related to widespread skin tightening, development of contractures, and painful tendon friction rubs. In addition, these patients are at high risk for internal organ involvement affecting the lungs, kidneys, gastrointestinal tract, and heart, particularly early in their disease course during the phase of progressive skin tightening\(^1\). Currently, there are limited therapeutic options for patients with dcSSc, and there is no approved therapy specifically for SSc. Several fibrotic pathways are implicated in the pathogenesis of SSc, including the platelet-derived growth factor receptor (PDGFR) and transforming growth factor-\(\beta\) (TGF-\(\beta\)) pathways\(^2\).

Imatinib is a tyrosine kinase inhibitor that has been shown to antagonize the PDGFR and TGF-\(\beta\) pathways through direct inhibition of PDGFR and c-Abl, a downstream kinase in both pathways\(^3\). Seven clinical trials of imatinib in SSc have been conducted with variable results because of different patient populations, dosing regimens, and study designs\(^4,5,6,7,8,9,10\). Our group performed a 12-month, single-arm, open-label, phase IIa clinical trial of the safety and efficacy of imatinib mesylate in 30 individuals with dcSSc, and observed significant improvements in skin thickening and forced vital capacity\(^4\). Sequential blood samples were collected during the clinical trial for biomarker analyses, in particular to identify markers of clinical improvement that could potentially facilitate individualized treatment\(^11\).

Multiple circulating cytokines, chemokines, and growth factors are dysregulated in SSc, and have been associated with disease subsets and features\(^12,13\). Measurement of cytokines, chemokines, and growth factors using multiplex platforms, such as Luminex, has the advantage of allowing the generation of multianalyte signatures or scores. These multianalyte metrics have the potential to better identify the clinical heterogeneity of SSc compared with single-analyte tests.

Autoantibodies, including antinuclear antibody, antitopoisomerase I (anti-Scl-70), anti-RNA polymerase III, and anticentromere antibody (ACA) are commonly measured in the clinical setting to support the diagnosis of SSc. Presence of specific autoantibodies has also been related to cutaneous subsets and clinical features of SSc\(^14\). Many other autoantibodies have been described in SSc, but corresponding laboratory tests are not widely available for clinical use\(^14\). Autoantigen microarrays allow multiplex measurement of autoantibodies\(^15\), including less common autoantibodies, making them an ideal platform for identification of novel disease associations.

In our current study, we investigated the cytokines, chemokines, growth factors, and autoantibodies in serum samples from a clinical trial of imatinib for the treatment of dcSSc using Luminex, ELISA, and autoantigen microarrays. We identified a multianalyte signature, based on the baseline levels of CD40 ligand, chemokine (C-X-C motif) ligand 4 (CXCL4), and anti-PM/Scl-100, that was predictive of clinical improvement. The signature was highly accurate in predicting clinical improvement in a validation cohort of serum samples from a clinical trial of nilotinib, a tyrosine kinase inhibitor that is structurally related to imatinib, for the treatment of dcSSc. Use of the signature to identify patients with the greatest likelihood of benefit from treatment with imatinib or nilotinib has the potential to guide individualized treatment of SSc.

**MATERIALS AND METHODS**

**Patients and controls.** As previously described\(^4\), our group performed a 1-year, phase IIa, single-arm, open-label clinical trial (ClinicalTrials.gov: NCT00555581) of imatinib mesylate in the treatment of dcSSc. Patients (n = 30) were treated with a target dose of imatinib (400 mg daily by mouth) for 12 months. A reduction in the modified Rodnan skin score (mRSS) ≥ 5 at 12 months was defined as a clinical improvement based on the defined minimally important difference in dcSSc\(^16\). Of the 30 patients enrolled, sera from 26 patients were collected at screening (1 month prior) or baseline (0 months). During the course of the trial, 1 patient withdrew by 6 months and 2 patients withdrew by 12 months. They were removed from analysis for those respective timepoints onward. Pretreatment sera from individuals who met the American College of Rheumatology criteria for dcSSc, collected as part of a 12-month trial of nilotinib in dcSSc\(^17\) (ClinicalTrials.gov: NCT01166139)\(^18\), were used as a validation cohort for our multianalyte signature. Baseline sera from 7 completers (of 10 enrolled) were analyzed. Baseline demographics are shown in Table 1. The institutional review board (IRB) at the Hospital for Special Surgery approved the above protocols (imatinib 27049 and nilotinib 10041).

The Stanford Chronic Immunologic Disease Registry and Repository provided age- and sex-matched healthy control sera (n = 8). The Stanford IRB approved the study (protocol #14734). Written consent was obtained from all individuals who participated in this study according to the Declaration of Helsinki.

| Table 1. Baseline patient characteristics of individuals with dcSSc. Values are n (%) unless otherwise specified. |
|-------------------------------------------------|--|---|
| Characteristics                                   | Imatinib, n = 26 | Nilotinib, n = 8 |
| Age, yrs, mean (range)                           | 48.6 (18–71)     | 47.9 (18–69)     |
| Women                                            | 21 (80.8)        | 6 (75)           |
| Race                                             |                 |                 |
| White                                            | 22 (84.6)        | 5 (62.5)         |
| Hispanic                                         | 2 (7.7)          | 0                |
| African American                                 | 0 (0)            | 3 (37.5)         |
| Undefined                                        | 2 (7.7)          | 0 (0)            |
| Disease duration, yrs, mean (range)*             | 3.3 (0.33–8)     | 0.75 (0.42–2)    |
| mRSS, median (range)                             | 26.5 (19–46)     | 27 (22–44)       |
| Scl-70+                                          | 7 (28)           | 2 (25)           |
| ANA+                                             | 16 (83.3)        | 7 (100)          |
| ACA+                                             | 0 (0)            | 0 (0)            |
| RNA Pol III**                                    | 1 (16.7)         | 5 (62.5)         |
| ILD involvement                                  | 13 (50)          | 2 (25)           |
| FVC % predicted, mean (range)                   | 84 (45–128)      | 77 (58–98)       |
| DLCO % predicted, mean (range)                  | 79 (45–127)      | 71 (55–85)       |

* Since first non-Raynaud symptom of SSc. ** Seven patients in the imatinib trial were tested for RNA Pol III antibodies. mRSS: modified Rodnan skin score; ANA: antinuclear antibody; ACA: anticentromere antibodies; ILD: interstitial lung disease; FVC: forced vital capacity.
clinical improvement during imatinib treatment. Elastic net fits linear models complexity (magnitude of the coefficient vector) 22. Baseline Luminex, between clinical improvement groups. No adjustments were made for (SAM) on the Luminex and microarray data 20. The 2-class unpaired package samr was used to perform significance analysis of microarrays Luminex 41-plex Human Cytokine/Chemokine Panel analysis with 3 additional analytes: C-reactive protein (CRP), CXCL4, and soluble L-selectin (EMD Millipore), per manufacturer’s instructions. See Supplementary Table 1 for a complete list of analytes (available with the online version of this article). All samples were run in duplicate and the means of raw mean fluorescence intensity (MFI) values were used. The average coefficient of variation (CV) was 7.32%. Samples with a CV ≥ 30% (<3% of samples) were excluded from the analyses.

Chemokine ELISA. Serum macrophage inflammatory protein-3β (MIP3β) and I-TAC were measured using human DuoSet ELISA kits (R&D Systems). We coated Nunc-Immuno Maxisorp 96-well plates (Thermo Scientific) with goat anti-human capture antibodies or 10 mg/ml bovine serum albumin (BSA) in phosphate buffered saline (PBS) overnight at 4°C. After washing 5x in wash buffer (PBS with 0.05% Tween), plates were blocked with blocking buffer (10 mg/ml BSA in PBS with 0.05% Tween). Plates were washed and probed with patient serum diluted 1:10 in blocking buffer. After washing, plates were probed with biotinylated goat anti-human detection antibodies in blocking buffer. Plates were washed and probed with streptavidin-conjugated Europium diluted in Delfia Assay Buffer (both by Perkin Elmer). Plates were washed, then incubated in Delfia enhancement buffer (Perkin Elmer) for 25 min at 37°C. The time-resolved fluorescence of each well was measured with a Wallac Victor model 1420 Multilabel Counter (Perkin Elmer). All patient samples were run in duplicate. For each sample, the fluorescence counts from the BSA-coated wells were subtracted from the respective analyte.

Autoantigen microarrays. We printed 28 SSc-associated autoantigens and 2 control features (PBS and goat anti-human secondary) on epoxy-coated glass slides (NEXTERION Slide E) using a VersArray ChipWriter Compact microarraying robot (BioRad). See Supplementary Table 2 (available with the online version of this article) for more information on the autoantigens. Microarrays were printed in a 12-pad format, with all features printed in triplicate. The microarrays were blocked with 5% nonfat milk (blotting grade; BioRad) in PBS, and washed 5x with wash buffer (PBS with 0.1% Tween-20). Patient serum diluted 1:200 in probing buffer (5% fetal calf serum in PBS with 0.1% Tween-20) was used to probe the microarrays in duplicate. After probing, the microarrays were washed 5x with wash buffer and stained with AlexaFluor 647-conjugated goat anti-human immunoglobulin G (IgG; Fcy fragment-specific) secondary (Jackson Immunoresearch). Microarrays were then washed at room temperature as follows: 5 quick washes in wash buffer, 5 min in wash buffer with gentle shaking, and two 5-min washes in PBS with gentle shaking. Finally, slides were dried at 1000x the force of gravity for 3 min.

Microarrays were scanned at 635 nm using a G2505C Microarray Scanner (Agilent). Images were gridged using GenePix Pro 7.0 software (Molecular Devices) and the MFI minus background fluorescence measurements used for analysis. The mean MFI of triplicate features was averaged across duplicate samples. Three samples (of 33) were removed from the analysis because their positive control feature (goat anti-human secondary) was negative.

Statistics. Calculations were performed with R version 3.0.219. The R package samr was used to perform significance analysis of microarrays (SAM) on the Luminex and microarray data20. The 2-class unpaired Wilcoxon test statistic was used with 1000 permutations. The pheatmap package was used to create hierarchically clustered heatmaps21. The Mann-Whitney U tests were used for comparison of chemokine and autoantibody levels between individuals with dcSSc and healthy controls, and between clinical improvement groups. No adjustments were made for multiple testing in Supplementary Figure 1 or Supplementary Figure 2 (available with the online version of this article).

The elastic net algorithm was used to create a predictive signature of clinical improvement during imatinib treatment. Elastic net fits linear models in a stepwise progression along a sequence of values that penalize model complexity (magnitude of the coefficient vector)22. Baseline Luminex, autoantigen microarray, and ELISA measurements as well as clinical history (Supplementary Table 3, available with the online version of this article) from the time of sampling from individuals with dcSSc in the imatinib clinical trial (n = 23 completers) were used as input variables. Prior to performing elastic net, missing values were imputed using k-nearest neighbors (k = 4) from the impute package23. Clinical measurement of ACA was removed prior to imputation because it was measured for only 8 individuals in the imatinib trial. Less than 6% of the combined Luminex, autoantigen microarray, and clinical variables required imputation. RNAP (RNA polymerase III antibody) and Sc1-70 were measured both clinically and using autoantigen microarrays. Measurements from both platforms were included as input for elastic net because the algorithm is capable of handling data where the number of predictors (p) is greater than the number of observations (n), as well as highly correlated predictors22. Continuous variables were log2 transformed prior to elastic net analysis.

The glmnet package was used to perform elastic net (α = 0.5) with a binomial response type24. Cross-validation (k-fold) was used to estimate the ideal elastic net penalty value (selecting the largest λ value within 1 standard error of the minimum mean squared error), and the coefficients at this value were used to calculate the signature for each individual patient with dcSSc. Variables with coefficients of 0 were removed from the model, which resulted in selection of relevant variables.

Receiver-operating characteristic (ROC) curve analysis was performed using the ROC package25. For all patients who completed the trial but did not provide sera at a given timepoint, we used last observation carried forward.

RESULTS

Luminex and ELISA analysis of sera from individuals with dcSSc. We used Luminex to measure the levels of 44 cytokines, chemokines, and growth factors in the baseline serum samples of individuals with dcSSc (n = 26) from the clinical trial of imatinib (and healthy controls, n = 8). See Supplementary Table 1 (available with the online version of this article) for a list of the Luminex analytes. To check the reliability of our measurements, we identified inflammatory mediators at significantly different levels between individuals with dcSSc at baseline and healthy controls using SAM (q < 0.001, fold-change > 2), and compared our results with published reports26. There was a high level of agreement between our measurements and the published studies because we identified 18 analytes that were at significantly higher levels in dcSSc (Figure 1), including CRP, etoxin, granulocyte macrophage colony-stimulating factor, interleukin-6 (IL-6), IL-8 (CXCL8), 10 kDa interferon γ-induced protein (IP10, CXCL10), monocyte chemoattractant proteins 1 and 3 (MCP1, CCL2 and MCP3, CCL7), and vascular endothelial growth factor, all of which had been previously observed27,28,29,30. Four individuals with dcSSc formed a relatively distinct cluster on the left side of the heatmap. Analysis of their clinical variables showed that they had significantly greater disease duration and significantly lower hemoglobin than the other patients with dcSSc.

Our Luminex analysis showed there were increased levels of multiple interferon-regulated chemokines in the sera of individuals with dcSSc, including MCP1, MCP3, and IP10. We used ELISA to evaluate the levels of 2 additional interferon-regulated chemokines, MIP3β (CCL19) and inter-
feron-inducible T-cell α chemoattractant (ITAC, CXCL11), and found that they were also significantly elevated compared with healthy controls (Supplementary Figure 1, available with the online version of this article)29.

Autoantigen microarray analysis of sera from individuals with dcSSc. We profiled the autoantibodies present in the baseline sera of individuals with dcSSc from the clinical trial of imatinib (n = 24) and healthy controls (n = 7) using autoantigen microarrays featuring 28 known SSc autoantigens and controls (Supplementary Table 2, available with the online version of this article). Our measurements were of high quality because the SAM algorithm identified significantly higher IgG reactivity to multiple known SSc autoantigens, including Scl-70 (topoisomerase I), PM/Scl-75, RNA polymerase III, and nucleophosmin 1, in individuals with dcSSc compared with healthy controls (q < 0.001, fold-change > 2; Figure 2). Further, a high level of agreement was observed between the microarray results and clinical antibody tests (Supplementary Figure 2, available with the online version of this article). One healthy control clustered with individuals who have dcSSc. Other groups observed this previously31, and we concluded that it reflected variability in self-reactivity in the healthy population.

Identification of a multianalyte signature associated with clinical improvement during treatment with imatinib. We used the elastic net multiple regression technique to identify a multianalyte signature that is predictive of clinical improvement in dcSSc during treatment with imatinib22. Input variables used were baseline Luminex, autoantigen microarray, and ELISA measurements as well as clinical history (Supplementary Table 3, available with the online version of this article) from the time of sampling of individuals with dcSSc in the imatinib clinical trial (n = 23 completers). Clinical improvement in skin thickness
(reduction in mRSS ≥ 5 at 12 mos) was used as the outcome of interest. A signature, corresponding to the following linear equation based on serum measurements of CD40L, CXCL4, and anti-PM/Scl-100, was identified by elastic net (coefficients have been rounded to 3 decimal places; Supplementary Figure 3, available with the online version of this article):

\[
\text{Score} = -1.474 + (0.031)\log_2 (\text{CD40L}) + (0.060)\log_2 (\text{CXCL4}) + (0.076)\log_2 (\text{PM})
\]

The equation was used to calculate scores for each individual patient with dcSSc (CD40L and CXCL4 represent Luminex values, and anti-PM/Scl-100 (PM) was measured...
patients who have a good prognosis in terms of skin thickness and inhibits PDGFR and other kinases. We used sera from a clinical trial of nilotinib for the treatment of dcSSc, and observed significant improvement in mRSS at 6 months. Nilotinib is a tyrosine kinase inhibitor that is structurally related to imatinib. It is a treatment for patients with diffuse cutaneous disease. We identified a multianalyte signature in individuals with SSc40,41. In agreement with our findings, testing whether baseline measurement of cytokines, chemokines, growth factors, or autoantibodies was predictive of clinical improvement (decrease in mRSS ≥ 5) during treatment with imatinib. While the levels of individual analytes were not significantly associated with clinical improvement (data not shown), the elastic net algorithm identified a multianalyte signature, based on baseline levels of CD40L, CXCL4, and anti-PM/Scl-100, that was predictive and accurate (AUC = 0.91).

Our group performed a 12-month, single-arm, open-label clinical trial of the safety and efficacy of nilotinib in 10 individuals with dcSSc, and observed significant improvements in skin thickening at 6 months. Nilotinib is a tyrosine kinase inhibitor that is structurally related to imatinib. It is a more potent inhibitor of the Abl kinase domain than imatinib, and inhibits PDGFR and other kinases. We used sera collected during the clinical trial to validate the signature in an independent cohort and found that it was robust (AUC = 0.92).

Limitations of our study include the relatively small sample size and the lack of placebo control groups in the original trials. It is possible that the signature identifies patients who have a good prognosis in terms of skin thickness rather than response to tyrosine kinase inhibitors. Testing the signature in a placebo-controlled trial would clarify whether the signature’s association with clinical improvement is specific to drug treatment. It will also be interesting to investigate whether the signature is predictive of clinical improvement in clinical trials of other drugs targeting different pathways in dcSSc in the future.

Multiple lines of evidence suggest that the analytes in our signature are biologically plausible as biomarkers of clinical improvement during treatment with imatinib or nilotinib. Circulating levels of CXCL4 were identified as a biomarker of SSc (especially diffuse cutaneous disease) associated with skin fibrosis and pulmonary disease and predictive of progression in skin and lung fibrosis, as well as pulmonary arterial hypertension. High serum levels of CXCL4 would contribute to an increased multianalyte signature, suggesting that these patients may benefit from treatment with imatinib or nilotinib. A caveat to our findings is that we measured CXCL4 in serum rather than plasma. CXCL4 levels in serum may not reflect physiological conditions because of platelet activation during serum preparation. Activated T cells appear to be involved in SSc pathogenesis. Levels of CD40L on the surface of activated CD4+ T lymphocytes and circulating levels of soluble CD40L are elevated in SSc compared with controls. T cells from mice lacking Abl kinases, a molecular target of imatinib and nilotinib, exhibit defective activation in response to T cell receptor stimulation.

In a 6-month clinical trial of imatinib for the treatment of dcSSc, Pope et al. found that the change in plasma levels of soluble CD40L was significantly negatively correlated with change in the physician’s global assessment. This suggests that individuals with increased serum CD40L (and multianalyte signatures) may benefit from imatinib and nilotinib treatment. PM/Scl-100 antibodies are found in 4.9%–7.1% of individuals with SSc. In agreement with our findings, patients with PM/Scl antibodies were previously found to respond favorably to moderate immunosuppression.

This study builds on our previous work in which we identified a transcriptional signature of imatinib-responsive genes in the lesional skin of 2 individuals with dcSSc. The current signature has the advantages of being predictive of clinical improvement, and measured using serum, which is less invasive than skin biopsy.

We identified a multianalyte signature in individuals with dcSSc, based on serum levels of CD40L, CXCL4, and anti-PM/Scl-100 that is predictive of clinical improvement during treatment with imatinib. We tested the signature’s performance in an independent trial of nilotinib for the treatment of dcSSc and found that it was highly accurate. Further testing in randomized, placebo-controlled studies will be required to fully validate the signature.

ACKNOWLEDGMENT

We thank the individuals with diffuse cutaneous systemic sclerosis and the healthy volunteers who participated in this research. We also thank Yael.
ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES


